Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosciens BiopharmaCSCIF 61 5-Year Share Buyback Ratio is -13.30 as of Jun. 2026. GuruFocus rates CSCIF with a GF Score™ of 61/100 and a GF Value™ of $7.02 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,131 Biotechnology companies, Cosciens Biopharma ranks worse than 56.94% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cosciens Biopharma's current 5-Year Share Buyback Ratio was -13.30%.
CSCIF's 5-Year Share Buyback Ratio is ranked worse than 56.94% of 1131
companies
in the Biotechnology industry
Industry Median: -10.3
vs CSCIF: -13.30
Cosciens Biopharma (OTCPK:CSCIF) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Cosciens Biopharma 5-Year Share Buyback Ratio Related Terms
CSCIF vs VRTX, REGN, RVMD: 5-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Cosciens Biopharma's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma 5-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's 5-Year Share Buyback Ratio falls into.
Cosciens Biopharma 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of -13.30 mean?
Cosciens Biopharma (CSCIF) has a 5-Year Share Buyback Ratio of -13.30 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Cosciens Biopharma and its competitors. According to the industry distribution chart, Cosciens Biopharma ranks #644 out of 1131 companies in the Biotechnology industry, placing it in the top 56.9%.
Is Cosciens Biopharma's 5-Year Share Buyback Ratio too high?
Cosciens Biopharma's current 5-Year Share Buyback Ratio is -13.30. Based on the distribution chart, Cosciens Biopharma ranks #644 out of 1131 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's 5-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cosciens Biopharma ranks #644 out of 1131 companies for 5-Year Share Buyback Ratio. This places Cosciens Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Biotechnology company?
A good 5-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Cosciens Biopharma and its competitors. Cosciens Biopharma's current 5-Year Share Buyback Ratio is -13.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.02, compared to a current price of $5.50 — trading 21.7% below its estimated fair value. The current 5-Year Share Buyback Ratio is -13.30. Cosciens Biopharma's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current 5-Year Share Buyback Ratio is -13.30 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCIF) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued.
The current stock price of $5.50 is trading 21.7% below its estimated GF Value™ of $7.02.
GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.
Key valuation signals for CSCIF:
5-Year Share Buyback Ratio: -13.30
GF Value™: $7.02 vs. price of $5.50 (21.7% below fair value)
No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score
Get the complete analysis for CSCIF
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCIF has been successfully added to your 
